prescription drugs
AARP is supporting a bill that would help federal regulators share information as they review patents for certain medicines and medical technologies.
An executive order signed by New Mexico Gov. Michelle Lujan Grisham will create a panel tasked with finding ways to lower prescription drug prices.
Successful deprescribing (that is, reducing or eliminating certain drugs that may be causing harm) in the course of routine care may depend on strengthening and elevating the information that is available to consumers.
AARP and more than 70 other organizations are demanding the Senate advance legislation to lower prescription drug prices by Memorial Day.
Washington is the latest state to adopt an affordability board to help rein in prescription drug prices.
Prescription drug abuse is a serious and growing public health issue in the United States. While media attention and policy efforts often focus on younger populations, older adults are not immune to the problem. A new AARP Public Policy Institute report finds that while the prevalence of…
Screening for osteoporosis among high-risk populations, including postmenopausal women, is essential. Women found to have low bone density due to osteoporosis or osteopenia (a precursor to osteoporosis) can reduce their risk of future bone fracture with lifestyle changes and drug therapies. The…
Since 2006, Medicare beneficiaries have had access to outpatient prescription drug coverage through Medicare Part D. The standard benefit under Part D includes an annual deductible, an initial coverage period when enrollees pay 25 percent of their drug costs, and catastrophic coverage that limits…
Fragility fractures are a common — but not inevitable — part of aging. These bone fractures, which occur during normal activities or following a fall, are a leading cause of pain, disability and loss of independence among older adults. Approximately half of all women and a quarter of all men age 50…
Turing Pharmaceuticals recently faced intense public criticism after the company bought a 62-year-old drug and increased its price by 5,000 percent. Turing’s unusually outspoken chief executive officer, Martin Shkreli, strongly defended the decision, even going so far as to argue that the new price…